Literature DB >> 23721513

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.

Chuanbing Zang1, Jan Eucker, Hongyu Liu, Annekatrin Coordes, Minoo Lenarz, Kurt Possinger, Christian Wilfried Scholz.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent aggressive lymphoma, with a great demand for novel treatments for relapsing and refractory disease. Constitutive activation of the phosphatidyl-inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is often detected in this lymphoma. Inhibition of this signaling cascade with the pan-class I PI3K inhibitor NVP-BKM120 decreased cell proliferation and increased apoptotic cell death. DLBCL proliferation was further decreased if NVP-BKM120-induced autophagy was blocked. Treatment with NVP-BKM120 was associated with an increase of the pro-apoptotic BH3-only proteins Puma and Bim and down-regulation of the anti-apoptotic Bcl-xL and Mcl-1. Translation of Bcl-xL and Mcl-1 is facilitated by cap-dependent mRNA translation, a process that was partially inhibited by NVP-BKM120. Overall, we demonstrated here the potential of NVP-BKM120 for the treatment of DLBCL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23721513     DOI: 10.3109/10428194.2013.806800

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  23 in total

1.  Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Authors:  Kai Xue; Juan J Gu; Qunling Zhang; Cory Mavis; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman; Ye Guo
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-28       Impact factor: 4.553

Review 2.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 3.  Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma.

Authors:  Joanna Rhodes; Daniel J Landsburg
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

4.  Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Authors:  A Lonetti; I L Antunes; F Chiarini; E Orsini; F Buontempo; F Ricci; P L Tazzari; P Pagliaro; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

Review 5.  Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy.

Authors:  Xinlei Yu; Yun Chau Long; Han-Ming Shen
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

6.  The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML.

Authors:  Reza Shiri Heris; Atieh Pourbagheri-Sigaroodi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  Indian J Hematol Blood Transfus       Date:  2021-04-01       Impact factor: 0.900

7.  Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.

Authors:  Caitlin M Stewart; Laure Michaud; Karissa Whiting; Dana W Y Tsui; Connie Lee Batlevi; Reiko Nakajima; Chelsea Nichols; Stephanie De Frank; Paul A Hamlin; Matthew J Matasar; John F Gerecitano; Pamela Drullinsky; Audrey Hamilton; David Straus; Steven M Horwitz; Anita Kumar; Craig H Moskowitz; Alison Moskowitz; Andrew D Zelenetz; Jurgen Rademaker; Gilles Salles; Venkatraman Seshan; Heiko Schöder; Anas Younes
Journal:  Clin Cancer Res       Date:  2021-10-06       Impact factor: 13.801

8.  Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.

Authors:  Chie Ishikawa; Masachika Senba; Naoki Mori
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 9.  Targeting autophagy in lymphomas: a double-edged sword?

Authors:  Han Zhang
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

10.  The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Authors:  Matteo Allegretti; Maria Rosaria Ricciardi; Roberto Licchetta; Simone Mirabilii; Stefania Orecchioni; Francesca Reggiani; Giovanna Talarico; Roberto Foà; Francesco Bertolini; Sergio Amadori; Maria Rosaria Torrisi; Agostino Tafuri
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.